EKF Diagnostics Holdings (LSE:EKF) Research & Development: £0.00 Mil (TTM As of Dec. 2025)


LSE:EKF EKF Diagnostics Holdings PLC LSE:EKF
54 GF Score
Price £0.27
GF Value £0.28
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is EKF Diagnostics Holdings Research & Development?

EKF Diagnostics Holdings LSE:EKF +0.75% 54 Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus rates LSE:EKF with a GF Score™ of 54/100 and a GF Value™ of £0.28 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. EKF Diagnostics Holdings's Research & Development for the six months ended in Dec. 2025 was £0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £0.00 Mil.

EKF Diagnostics Holdings  (LSE:EKF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

EKF Diagnostics Holdings Research & Development Related Terms

EKF Diagnostics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for EKF Diagnostics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EKF Diagnostics Holdings Research & Development Chart

EKF Diagnostics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

EKF Diagnostics Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:EKF
54GF Score
EKF Diagnostics Holdings PLC LSE:EKF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EKF Diagnostics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £0.00 Mil mean?
EKF Diagnostics Holdings (LSE:EKF) has a Research & Development of £0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on EKF Diagnostics Holdings and its competitors.
Is EKF Diagnostics Holdings' Research & Development too high?
EKF Diagnostics Holdings' current Research & Development is £0.00 Mil. Overall, EKF Diagnostics Holdings has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does EKF Diagnostics Holdings' Research & Development compare to ABT and SYK?
EKF Diagnostics Holdings' Research & Development of £0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on EKF Diagnostics Holdings and its competitors. EKF Diagnostics Holdings's current Research & Development is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EKF Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, EKF Diagnostics Holdings (LSE:EKF) is currently considered Fairly Valued. The stock's GF Value™ is £0.28, compared to a current price of £0.27 — trading 3.6% below its estimated fair value. The current Research & Development is £0.00 Mil. EKF Diagnostics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For EKF Diagnostics Holdings (LSE:EKF), the current Research & Development is £0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EKF Diagnostics Holdings (LSE:EKF) Overvalued in 2026?

Based on GuruFocus' analysis, EKF Diagnostics Holdings stock appears to be undervalued. The current stock price of £0.27 is trading 3.6% below its estimated GF Value™ of £0.28. GuruFocus considers EKF Diagnostics Holdings to be Fairly Valued.

Key valuation signals for LSE:EKF:

  • Research & Development: £0.00 Mil
  • GF Value™: £0.28 vs. price of £0.27 (3.6% below fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the LSE:EKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

EKF Diagnostics Holdings Business Description

Other Exchanges EKDHF:USALYF:Germany
Address 19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements.
54GF Score

Get the complete analysis for LSE:EKF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.27
Price
£0.28
GF Value